Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 25 of the 158 sources its claims cite were checked for support.
Abstract
Central hypogonadism is a clinical condition, characterized by sexual symptoms and low serum testosterone levels, due to an impaired function of the hypothalamus or pituitary gland. Testosterone replacement therapy (TRT) is the standard treatment for hypogonadism, but it has some disadvantages. TRT is not a good option in men wishing to preserve fertility, nor in men with (a high risk of) prostate cancer, polycythemia, thrombophilia and severe cardiovascular disease. In this review, we discuss alternative treatments for central hypogonadism. If reversible causes are present, non-pharmacological interventions can be therapeutic. Gonadotropins are a good alternative to TRT when fertility is desired in the near future though they require frequent injections. Clomiphene citrate and tamoxifen seem to be a safe alternative for the treatment of functional central hypogonadism in men, as several studies reported a significant increase in testosterone levels with these drugs. However, their use is off-label and data supporting the efficacy of clomiphene citrate and tamoxifen on hypogonadal symptoms are insufficient. For this reason, clomiphene citrate and tamoxifen should not be used in routine clinical practice to treat sexual symptoms in men with central hypogonadism.
Overview
CoChat Summary
## TL;DR
This review summarizes alternatives to testosterone replacement therapy (TRT) for men with central hypogonadism, especially when fertility must be preserved or TRT is otherwise unsuitable. The authors conclude that gonadotropins are the best-supported alternative for fertility-directed treatment, while clomiphene citrate and tamoxifen may raise testosterone in functional central hypogonadism but should not be used routinely for sexual symptoms because symptom-benefit data are insufficient.
## Key findings
- TRT is described as the standard treatment for hypogonadism, but it is not a good option for men wishing to preserve fertility and is contraindicated or unsuitable in men with prostate cancer risk, polycythemia, thrombophilia, severe cardiovascular disease, and some other conditions.
- Gonadotropin therapy induced spermatogenesis in 75% of patients in one meta-analysis of men with hypogonadotropic hypogonadism and azoospermia; in another combined analysis of 100 patients, spermatogenesis was induced in 84% and 69% reached sperm concentrations ≥1.5 × 10^6/mL.
- A retrospective study in hypogonadotropic hypogonadism found hCG alone led to testicular growth in 42/84 (50%) and spermatogenesis in 34/84 (40%), while hCG + hMG led to testicular growth in 56/74 (76%) and spermatogenesis in 48/74 (65%).
- Clomiphene citrate and tamoxifen were reported in several studies to significantly increase testosterone, but evidence for symptom improvement is inconsistent; one study in 86 men showed improvement in 5/10 ADAM questions, while an RCT in 78 obese men found no difference in overall ADAM score after 12 weeks.
- In one retrospective analysis of 400 men treated with clomiphene citrate for a mean of 25.5 months, side effects were reported in 8%; another study of 46 men reported no side effects over 12 months.
## Methods
- This is a narrative review of treatments for central hypogonadism, organized into non-pharmacological interventions, gonadotropins, pulsatile GnRH, SERMs (clomiphene citrate, tamoxifen), and aromatase inhibitors.
- The paper synthesizes evidence from studies cited in the text, including meta-analyses, randomized controlled trials, retrospective studies, and small observational studies; no new patient sample is presented.
- The main analysis is qualitative comparison of treatment options based on effects on testosterone, fertility/spermatogenesis, hypogonadal symptoms, and adverse effects.
## Limitations
- The paper states that studies of clomiphene citrate and tamoxifen are often heterogeneous, frequently lack clear descriptions of the study population, and often do not distinguish organic from functional central hypogonadism.
- It explicitly notes that high-quality RCTs with clear population definitions and long-term follow-up are missing for clomiphene citrate and tamoxifen, so evidence is insufficient to justify their routine use for sexual symptoms.
- Evident from the text: this is a review, so conclusions depend on the quality and consistency of previously published studies rather than direct original data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
23 Valid · 0 Not valid · 89 Not checked · 16 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As functional hypogonadism is associated with the use of certain drugs, hyperprolactinemia, obesity and chronic diseases, such as type 2 diabetes, treatment of these causes can help normalize testosterone levels [9].”
§ Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy > 2. Non-Pharmacological Treatment
What the sources say
- Partly supportedcites [9] Grossmann, 2017, A Perspective on Middle-Aged and Older Men with Functional Hypogonadism: Focus on Holistic Management, J. Clin. Endocrinol. Metab. sourceExperimental — accuracy not yet measured
The Abstract (page not provided) links functional hypogonadism to obesity, comorbid illness, and medications such as opioids or glucocorticoids; “Optimization of Chronic Disease” specifically identifies type 2 diabetes. The paper says these conditions may improve with treatment, but its definition excludes hyperprolactinemia as a specific pathologic cause that should be ruled out. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“As functional hypogonadism is associated with the use of certain drugs, hyperprolactinemia, obesity and chronic diseases, such as type 2 diabetes, treatment of these causes can help normalize testosterone levels [9].”
§ Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy > 2. Non-Pharmacological Treatment
What the sources say
- Partly supportedcites [9] Grossmann, 2017, A Perspective on Middle-Aged and Older Men with Functional Hypogonadism: Focus on Holistic Management, J. Clin. Endocrinol. Metab. sourceExperimental — accuracy not yet measured
The Conclusions (page unavailable) say that weight loss and management of comorbidities may reverse HPT-axis suppression enough to normalize testosterone; stopping offending medications may also increase levels, though these measures may be insufficient. The Abstract (page unavailable) treats hyperprolactinemia differently: it is a specific pathology to exclude from the paper’s defined group of men with functional hypogonadism, not one of the causes addressed by those management recommendations. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Moreover, the role of TRT to treat men with functional or late-onset hypogonadism remains controversial because of unclear indications and potential side effects [1,9].”
§ Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Salonia, 2019, Paediatric and adult-onset male hypogonadism, Nat. Rev. Dis. Prim. source
- Supportedcites [9] Grossmann, 2017, A Perspective on Middle-Aged and Older Men with Functional Hypogonadism: Focus on Holistic Management, J. Clin. Endocrinol. Metab. source
The Testosterone Therapy section says decisions about TRT must weigh uncertain long-term benefits and risks, exclude contraindications, and target men with specific symptoms and consistently low testosterone. The Characteristics section explains why symptoms and low testosterone do not always establish androgen deficiency, supporting the claim that indications are unclear. Page numbers were not provided in our copy. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Several studies with a very low-calorie ketogenic diet showed a positive effect of this diet on body mass index, glycemic control and insulin resistance.”
§ Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy > 2. Non-Pharmacological Treatment
What the sources say
- Supportedcites [23] Mongioì, L.M., Cimino, L., Condorelli, R.A., Magagnini, M.C., Barbagallo, F., Cannarella, R., la Vignera, S., and Calogero, A.E. (2020). Effectiveness of a Very Low Calorie Ketogenic Diet on Testicular Function in Overweight/Obese Men. Nutrients, 12. source
The Results report significant improvements in BMI, fasting glucose, insulin, and HOMA index after VLCKD. The Discussion also describes previous studies finding BMI reductions and a review reporting improved glycemic control and a lower HOMA index. (LLM, conf=0.91)
- Supportedcites [24] La Vignera, S., Cannarella, R., Galvano, F., Grillo, A., Aversa, A., Cimino, L., Magagnini, C.M., Mongioì, L.M., Condorelli, R.A., and Calogero, A.E. (2020). The ketogenic diet corrects metabolic hypogonadism and preserves pancreatic ß-cell function in overweight/obese men: A single-arm uncontrolled study. Endocrine, 1–8. source
The Results report significant decreases in BMI, glycaemia, and the HOMA index after a very low-calorie ketogenic diet. The Discussion also reports that several studies found improvements in glycaemic measures and insulin resistance. The study itself was single-arm and uncontrolled, so its before-and-after results do not establish causation on their own. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A small study in 20 patients with overweight or obesity and functional hypogonadism showed that a very low-calorie ketogenic diet during 12 weeks resulted in a mean increase in total testosterone levels of around 218% (± 53.9%) [24].”
§ Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy > 2. Non-Pharmacological Treatment
What the sources say
- Supportedcites [24] La Vignera, S., Cannarella, R., Galvano, F., Grillo, A., Aversa, A., Cimino, L., Magagnini, C.M., Mongioì, L.M., Condorelli, R.A., and Calogero, A.E. (2020). The ketogenic diet corrects metabolic hypogonadism and preserves pancreatic ß-cell function in overweight/obese men: A single-arm uncontrolled study. Endocrine, 1–8. source
The Abstract Results (page not provided) report 20 patients and a mean 218.1 ± 53.9% increase in total testosterone. The Abstract Methods (page not provided) specify that the patients had overweight or obesity and metabolic hypogonadism and followed a very low-calorie ketogenic diet for 12 weeks. (LLM, conf=0.95)
plainstates a causen = 20- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
82 more claims · 11 with their cited sources checked
Create a free account to see all 128 claims and to verify the 11 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 9
Citations
Cites
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736 · cited 10×
“According to the Endocrine Society and European Academy of Andrology guidelines, only men with symptoms or signs of testosterone deficiency and repeatedly low serum testosterone concentrations on morning blood samples, taken in standardized conditions, should be diagnosed with hypogonadism [2,3].”
BackgroundMethodInfluentialIdentification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 1×
“Therefore, the European Male Aging Study (EMAS) group suggests that only ageing men with concomitantly low total and free serum testosterone levels, and at least three sexual symptoms should be diagnosed with late-onset hypogonadism [10,11].”
BackgroundSelf-citationWu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939 · cited 1×
“This clinical syndrome is associated with obesity, metabolic syndrome and chronic diseases [12,13].”
BackgroundSelf-citationBoehm, U., Bouloux, P.-M., Dattani, M. T., de Roux, N., Dodé, C., Dunkel, L., Dwyer, A. A., Giacobini, P., Hardelin, J.-P., Juul, A., et al. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.112 · Cited by 874 · cited 5×
“For this reason, combined gonadotropin treatment is preferred over hCG monotherapy in patients with a lack of testicular development [5].”
BackgroundInfluentialEffect of Lifestyle Changes on Erectile Dysfunction in Obese Men: A Randomized Controlled Trial
Esposito, K., Giugliano, F., Di Palo, C., Giugliano, G., Marfella, R., D'Andrea, F., D'Armiento, M., & Giugliano, D. (2004) · JAMA · doi:10.1001/jama.291.24.2978 · Cited by 841 · cited 1×
“Furthermore, weight loss by lifestyle modifications is associated with improvement in sexual function, measured by the International Index of Erectile Function [25].”
MethodBacon, C. G., Mittleman, M. A., Kawachi, I., Giovannucci, E., Glasser, D. B., & Rimm, E. B. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00005 · Cited by 832 · cited 1×
“Obesity increases the risk of erectile dysfunction in this population with 30% [19].”
BackgroundCorona, G., Goulis, D. G., Huhtaniemi, I., Zitzmann, M., Toppari, J., Forti, G., Vanderschueren, D., & Wu, F. C. (2020) · Andrology · doi:10.1111/andr.12770 · Cited by 431 · cited 3×
“According to the Endocrine Society and European Academy of Andrology guidelines, only men with symptoms or signs of testosterone deficiency and repeatedly low serum testosterone concentrations on morning blood samples, taken in standardized conditions, should be diagnosed with hypogonadism [2,3].”
BackgroundMethodSelf-citationCorona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0955 · Cited by 414
Travison, T. G., Araujo, A. B., Kupelian, V., O’Donnell, A. B., & McKinlay, J. B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1859 · Cited by 410
Camacho, E. M., Huhtaniemi, I. T., O'Neill, T. W., Finn, J. D., Pye, S. R., Lee, D. M., Tajar, A., Bartfai, G., Boonen, S., Casanueva, F. F., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0890 · Cited by 392
Self-citation
Cited by
Insights and implications of sexual dimorphism in osteoporosis
Zhang, Y., Xie, N., Sun, X., Nice, E. C., Liou, Y., Huang, C., Zhu, H., & Shen, Z. (2024) · Bone Research · doi:10.1038/s41413-023-00306-4 · Cited by 184
Jin, J., Xu, Z., Zhang, L., Zhang, C. M., Zhao, X., Mao, Y., Zhang, H., Liang, X., Wu, J., Yang, Y., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2167172 · Cited by 160
Roychoudhury, S., Chakraborty, S., Choudhury, A. P., Das, A., Jha, N. K., Sláma, P., Nath, M., Massányi, P., Ruokolainen, J., & Kesari, K. K. (2021) · Antioxidants · doi:10.3390/antiox10060837 · Cited by 145
Kharbech, O., Sakouhi, L., Massoud, M. B., Mur, L. A. J., Corpas, F. J., Djebali, W., & Chaoui, A. (2020) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2020.10.017 · Cited by 103
The emerging roles of bacterial proteases in intestinal diseases
Caminero, A., Guzman, M., Libertucci, J., & Lomax, A. E. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2181922 · Cited by 92
Metadata
- Authors
- Ide, V., Vanderschueren, D., & Antonio, L.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Corresponding author
- Antonio, Leen
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-12-22
- Volume
- 22
- Issue
- 1
- Pages
- 21
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7792781
- OpenAlex
- W3114028270
- Cited by
- 101
- References
- 69
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 33 · 2023: 25 · 2022: 11 · 2021: 4 · 2020: 1
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- central hypogonadism, testosterone replacement therapy, alternative treatment, gonadotropins, clomiphene citrate, tamoxifen, male hypogonadism, fertility preservation, off-label drug use, sexual symptoms, testosterone levels
- MeSH terms
- Androgens, Clomiphene, Fertility, Humans, Hypogonadism, Male, Testosterone, Treatment Outcome, Hormone Replacement Therapy, Selective Estrogen Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy. https://app.cochat.ai/papers/10.3390/ijms22010021
- The paper
- Ide, V., Vanderschueren, D., & Antonio, L. (2020). Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22010021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.